Exbio — Research products — Antibodies — CD and related antigens — Anti-Ms CD105 Purified

Anti-Ms CD105 Purified

Regulatory status

RUO

Antigen

CD105

Clone

MJ7/18

Format

Purified

Reactivity

Mouse

Application

IP, WB, FC (QC tested), IHC-F

Variant

0.1 mg

11-714-C100

In stock

88.00 USD

0.025 mg

11-714-C025

Delivery 1 week

44.00 USD

Variant

0.1 mg

11-714-C100

In stock

88.00 USD

0.025 mg

11-714-C025

Delivery 1 week

44.00 USD

Contact distributor

Product details

Description

References

SDS download

Isotype

Rat IgG2a kappa

Specificity

The rat monoclonal antibody MJ7/18 reacts with an extracellular epitope of CD105 (Endoglin), a 90 kDa type I homodimerizing membrane glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow.

Application

IP, WB, FC (QC tested), IHC-F

Application details

Flow cytometry: Recommended dilution: 1-4 μg/ml.

Reactivity

Mouse

Immunogen

Inflamed mouse skin

Concentration

1 mg/ml

Preparation

Purified by protein-G affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

Endoglin, END, ENG

Antigen description

CD105 (endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFbetaR-2 as a receptor for TGFbeta-1 and TGFbeta-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonises the inhibitory effects of TGFbeta-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.

Entrez Gene ID 13805

UniProt ID Q63961

Product specific references:

Ge AZ, Butcher EC: Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-beta ligand. Gene. 1994 Jan 28;138(1-2):201-6.
PubMed

Herouet C, Cottin M, LeClaire J, Enk A, Rousset F: Contact sensitizers specifically increase MHC class II expression on murine immature dendritic cells. In Vitr Mol Toxicol. 2000 Summer;13(2):113-23.
PubMed

Dassler K, Roohi F, Lohrke J, Ide A, Remmele S, Hütter J, Pietsch H, Pison U, Schütz G: Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles. Invest Radiol. 2012 Jul;47(7):383-91
PubMed

Rosu-Myles M, She YM, Fair J, Muradia G, Mehic J, Menendez P, Prasad SS, Cyr TD: Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells. PLoS One. 2012;7(6):e38954. doi: 10.1371/journal.pone.0038954.
PubMed

Cho SK, Bourdeau A, Letarte M, Zúñiga-Pflücker JC: Expression and function of CD105 during the onset of hematopoiesis from Flk1(+) precursors. Blood. 2001 Dec 15;98(13):3635-42.
PubMed

Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun;25(3B):1851-64.
PubMed

Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M: Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res. 2010 Apr 1;86(1):12-9. doi: 10.1093/cvr/cvp332.
PubMed